



**Date:** May 26, 2022

**Subject:** Ortho Clinical Diagnostics Holdings plc – Contract Adjustment  
Option Symbol: OCDX  
New Symbol: QDEL1  
Date: 05/27/2022

**Contract Adjustment**

**Date:** May 27, 2022

**Option Symbol:** OCDX changes to QDEL1

**Strike Divisor:** 1

**Contracts Multiplier:** 1

**New Multiplier:** 100 (e.g., a premium of 1.50 yields \$150; a strike of 20 yields \$2,000.00)

**New Deliverable Per Contract:**

- 1) 10 (New) QuidelOrtho Corporation (QDEL) Common Shares
- 2) Cash in lieu of 0.55 fractional QDEL Common Shares
- 3) \$714.00 cash (\$7.14 x 100)

Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

**CUSIP:** (New) QDEL: 219798105

**Pricing**

Until the cash in lieu amount is determined, the underlying price for QDEL1 will be determined as follows:

$$QDEL1 = 0.1055 (QDEL) + 7.14$$

**Delayed Settlement**

The QDEL component of the QDEL1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the QDEL1 deliverable until the cash in lieu of fractional QDEL shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

## **Background**

On May 16, 2022, Shareholders of Ortho Clinical Diagnostics Holdings plc (OCDX) voted concerning the proposed merger with Quidel Corporation (QDEL), to form a new company named QuidelOrtho Corporation. The merger was approved and subsequently consummated before the open on May 27, 2022. As a result, each existing OCDX Common Share will be converted into the right to receive 0.1055 QDEL Common Shares plus \$7.14 Cash. Cash will be paid in lieu of fractional QDEL shares.

## **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).